|Bid||4.2000 x 1100|
|Ask||4.5500 x 1400|
|Day's Range||4.5500 - 4.7600|
|52 Week Range||2.7900 - 5.0000|
|Beta (3Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.17|
ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA. The ChromaDex management team is scheduled to present on Wednesday, May 22, at 1:30 p.m. Pacific Time. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients.
ChromaDex (CDXC) delivered earnings and revenue surprises of 0.00% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Los Angeles-based company said it had a loss of 15 cents per share. Losses, adjusted for stock option expense, were 11 cents per share. The natural products company posted revenue of $10 million in ...
- First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net.
ChromaDex Corp. (CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement. The transaction was led by international strategic investors. The transaction is expected to close on or about May 17, 2019, subject to the satisfaction of customary closing conditions. The convertible notes will automatically convert into shares of ChromaDex common stock 45 days following the closing. The convertible notes will convert at $4.59 per share (market closing price on May 7, 2019), or if a common stock financing occurs in the 45 day period following the closing with a purchase price of less than $4.59 per share, at the price per share at which shares are issued in that financing.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you're interested in ChromaDex Corporation (NASDAQ:CDXC), then you might want to consider its beta...
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES, May 02, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its.
ChromaDex Corp. (CDXC) announced today a new distribution partnership for TRU NIAGEN® with Vancouver-based WELL Health Technologies Corp. (WELL.V) who intends on distributing TRU NIAGEN® via its partner network of pharmacy and other allied health businesses. According to Orbis Research, the $250 billion emerging anti-aging category is expected to reach some $331 billion by the year 2021, with rapid growth fueled by advancements in science and technology, and an aging global population. “Given the size of the global market, and the access to a key influencer group in British Columbia, we believe this partnership is an important milestone in our global expansion strategy,” said ChromaDex CEO Rob Fried.
ChromaDex Corp. (CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen is now available in 36 Showcase stores in the greater Toronto area as well as Showcase’s online store. “Tru Niagen appeals to health-conscious and high-performing consumers seeking products for a better life—this makes it a natural fit for Showcase, which attracts discerning customers seeking innovative products and emerging brands," said ChromaDex CEO Rob Fried.
ChromaDex Corp. (CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen®) helps maintain heart function in mice by stimulating a conserved cellular response called the “mitochondrial unfolded protein response” (UPRmt) that helps maintain mitochondrial function. The study also presents preliminary human data to support future testing of NR in humans.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! While not a mind-blowing move, it is good to see that the ChromaDex Corporation (NASDAQ:CDXC) share price has gained 23% i...
ChromaDex Corp. (CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world’s foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will speak at the Sixth Annual Biohacking Conference, a three-day immersive experience for the human performance industry. Hosted by Upgrade Labs, the conference runs Friday, April 5 through Sunday, April 7, 2019 at the Beverly Hilton Hotel in Los Angeles. The breakout session will explain cellular metabolism and the role of NAD as a key coenzyme in electron transport, which plays a crucial role in energy production for the body. Dr. Brenner will also reveal how metabolic stressors can compromise one’s NAD pool and why optimal NAD levels are important to enjoy a more resilient life.
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA. The ChromaDex management team is scheduled to present on Monday, March 18, at 3:30 p.m. Pacific Time. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. For more information about the conference or to schedule a one-on-one meeting with ChromaDex management, please contact your ROTH representative.
ChromaDex Corp. (CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at SXSW®, as it marks the achievement of attaining over 160 research collaborations around the world on its patented NIAGEN® (nicotinamide riboside) ingredient. "To help SXSW® attendees who need an extra boost in their busy lives, we'll be providing samples of Tru Niagen and discussing the science that disrupted the multi-billion-dollar anti-aging category with the discovery of nicotinamide riboside by Dr. Charles Brenner," says Frank Jaksch, ChromaDex Co-Founder and Executive Chairman.
- Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million - Fourth Quarter 2018 Highlights vs..
ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39th Annual Cowen Heath Care Conference at the Boston Marriott Copley Place in Boston, MA. The ChromaDex management team is scheduled to present on Monday, March 11, at 4:50 p.m. ET. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day.
LOS ANGELES, Feb. 28, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., Mar. 7, 2019 at 4:30 p.m. Eastern time to discuss its.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! ChromaDex Corporation (NASDAQ:CDXC), which is in the life sciences business,Read More...
ChromaDex Corp. (CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring physiological benefits to mothers and offspring. Conducted at the University of Iowa by Principal Investigator Dr. Charles Brenner, the Roy J. Carver Chair & Head of Biochemistry at the University of Iowa, as well as a founding co-director of the University of Iowa Obesity Initiative and Chief Scientific Advisor of ChromaDex, the study results were published yesterday in the journal Cell Reports.